US stocks: Summit shares drop after US FDA declines to approve lung cancer drug
Economic Times
Summit Therapeutics shares dropped after the US FDA declined to approve its lung cancer drug ivonescimab due to insufficient trial benefits.
Summit Therapeutics faced a notable decline in share value following the FDA's
ruling on ivonescimab, which revealed insufficient overall survival benefits
during late-stage trials. Despite Summit's emphasis on regional survival
differences, analysts worry that this decision could have repercussions for
similar treatments in development. Investors now eagerly await new trial
results comparing ivonescimab with conventional lung cancer therapies.

